Palisade Bio, Inc. (PALI)
| Market Cap | 344.56M +11,124.4% |
| Revenue (ttm) | n/a |
| Net Income | -24.15M |
| EPS | -0.23 |
| Shares Out | 173.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,692,439 |
| Open | 2.100 |
| Previous Close | 2.090 |
| Day's Range | 1.960 - 2.170 |
| 52-Week Range | 0.530 - 2.855 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+428.97%) |
| Earnings Date | Aug 10, 2026 |
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and co... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for PALI stock is "Strong Buy." The 12-month stock price target is $10.5, which is an increase of 428.97% from the latest price.
News
Palisade Bio receives FDA clearance to start ulcerative colitis study
Palisade Bio (PALI) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for its oral drug candidate, PALI-2108. The clearance allows the company t...
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2...
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium
Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach
Palisade Bio Transcript: Jefferies Global Healthcare Conference 2026
A novel oral PDE4 inhibitor prodrug for IBD demonstrated strong safety and efficacy in early trials, with phase II studies in ulcerative colitis and Crohn's disease set to begin, backed by robust funding and a top-tier clinical team. The drug's targeted delivery and tolerability differentiate it from competitors.
Palisade Bio Slides: Corporate presentation
Palisade Bio has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
Management presentation to take place on Thursday, June 4 th at 3:45 PM ET Register for the webcast here Denver, CO, May 27, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or t...
Palisade Bio Slides: Corporate presentation
Palisade Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Palisade Bio files $300M mixed securities shelf
17:28 EDT Palisade Bio (PALI) files $300M mixed securities shelf
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance she...
Palisade Bio Registration statement: Registration filing
Palisade Bio filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Palisade Bio Quarterly report: Q1 2026
Palisade Bio has published its Q1 2026 quarterly earnings report on May 12, 2026.
Palisade Bio Earnings release: Q1 2026
Palisade Bio released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval
Palisade Bio Proxy statement: Proxy filing
Palisade Bio filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Palisade Bio Proxy statement: Proxy filing
Palisade Bio filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Palisade Bio Proxy statement: Proxy filing
Palisade Bio filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Palisade Bio Transcript: 25th Annual Needham Virtual Healthcare Conference
A novel oral PDE4 inhibitor prodrug for IBD showed strong early efficacy and safety in UC and Crohn's, with 100% response in a UC phase Ib and robust PK/PD in Crohn's. Phase II trials are set for 2024, supported by $135M in cash and a precision medicine approach.
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biop...
Palisade Bio initiated with an Outperform at Wolfe Research
Wolfe Research analyst Andy Chen initiated coverage of Palisade Bio (PALI) with an Outperform rating and $7 price target The firm sees a “quiet 2026,” but is bullish into ulcerative…
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Compa...
Palisade Bio Slides: Corporate presentation
Palisade Bio has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Palisade Bio reaction to PALI-2108 data ‘looks misaligned’, says Clear Street
Clear Street keeps a Buy rating and $12 price target on Palisade Bio (PALI), saying the decline in the stock price after the Phase 1B Clinical Study of PALI-2108 in…
Palisade Bio Transcript: Study result
Phase I-B data for PALI-2108 in fibrostenotic Crohn's disease showed strong safety, robust PK/PD, and early clinical activity, with 40% endoscopic response/remission in a refractory population. Once-daily oral dosing and dual anti-inflammatory/anti-fibrotic action support further development in broader Crohn's cohorts.
Palisade Bio Press release: Study result
Palisade Bio issued a press release on March 31, 2026, disclosing material business information to investors.